[ad_1]
German drug company Bayer and Johnson & Johnson subsidiary Janssen Pharmaceuticals will jointly pay $ 775 million (£ 587 million) to settle more than 25,000 lawsuits in federal and state courts, representing almost all outstanding claims against the best anticoagulant rivaroxaban (Xarelto).
Janssen has a license to sell rivaroxaban in the United States, while Bayer has developed the plasticizer and sells it elsewhere.
Neither company has acknowledged its responsibility and both have expressed their constant confidence in rivaroxaban, which still sells robustly around the world. Bayer's revenue was $ 4.07 billion last year and Janssen's rivaroxaban sales totaled $ 2.47 billion.
Bayer said "continue to believe in these affirmations …
Source link
